Page last updated: 2024-10-27

fluorouracil and Coronary Thrombosis

fluorouracil has been researched along with Coronary Thrombosis in 4 studies

Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.

Coronary Thrombosis: Coagulation of blood in any of the CORONARY VESSELS. The presence of a blood clot (THROMBUS) often leads to MYOCARDIAL INFARCTION.

Research Excerpts

ExcerptRelevanceReference
"Capecitabine is an orally available chemotherapeutic agent that is converted to 5-fluorouracil (5-FU) after absorbtion."5.38Acute myocardial infarction after capecitabine treatment: not always vasospasm is responsible. ( Celiker, E; Eren, M; Güvenç, TS; Ilhan, E; Ozcan, KS, 2012)
"5-fluorouracil (5FU) is a largely employed antimetabolite, responsible for several well-known toxicities like hand-foot syndrome, diarrhoea, mucositis or leucopenia."2.42[Cardiotoxicity of 5-fluorouracil]. ( Barry, S; Cohen, A; Debourdeau, P; Teixeira, L; Tournigand, C, 2004)
"Oral capecitabine is a prodrug of 5-fluorouracil that has been used into the management of multiple cancers because of the convenience of administration and efficacy at least comparable with 5-fluorouracil."1.40Acute coronary artery thrombosis and vasospasm following capecitabine in conjunction with oxaliplatin treatment for cancer. ( Cleator, S; Dzaye, O; Nihoyannopoulos, P, 2014)
"Capecitabine is an orally available chemotherapeutic agent that is converted to 5-fluorouracil (5-FU) after absorbtion."1.38Acute myocardial infarction after capecitabine treatment: not always vasospasm is responsible. ( Celiker, E; Eren, M; Güvenç, TS; Ilhan, E; Ozcan, KS, 2012)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (50.00)29.6817
2010's2 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Dzaye, O1
Cleator, S1
Nihoyannopoulos, P1
Güvenç, TS1
Celiker, E1
Ozcan, KS1
Ilhan, E1
Eren, M1
Teixeira, L1
Barry, S1
Debourdeau, P1
Cohen, A1
Tournigand, C1
Roncalli, J1
Delord, JP1
Galinier, M1
Massabuau, P1
Lescure, M1
Fauvel, JM1
Azria, D1

Reviews

1 review available for fluorouracil and Coronary Thrombosis

ArticleYear
[Cardiotoxicity of 5-fluorouracil].
    Bulletin du cancer, 2004, Volume: 91 Suppl 3

    Topics: Antimetabolites, Antineoplastic; Capecitabine; Coronary Thrombosis; Coronary Vessels; Deoxycytidine;

2004

Other Studies

3 other studies available for fluorouracil and Coronary Thrombosis

ArticleYear
Acute coronary artery thrombosis and vasospasm following capecitabine in conjunction with oxaliplatin treatment for cancer.
    BMJ case reports, 2014, 09-22, Volume: 2014

    Topics: Adult; Antineoplastic Agents; Capecitabine; Colonic Neoplasms; Coronary Angiography; Coronary Thromb

2014
Acute myocardial infarction after capecitabine treatment: not always vasospasm is responsible.
    Chinese medical journal, 2012, Volume: 125, Issue:18

    Topics: Capecitabine; Coronary Thrombosis; Coronary Vasospasm; Deoxycytidine; Female; Fluorouracil; Humans;

2012
Bevacizumab in metastatic colorectal cancer: a left intracardiac thrombotic event.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:7

    Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2006